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Abstract
Allelic loss of chromosome 1p is frequently observed in oligodendroglioma. We screened 177
oligodendroglial tumors for 1p deletions and found 6 tumors with localized 1p36 deletions. Several
apoptosis regulation genes have been mapped to this region, including Tumor Protein 73 (p73), DNA
Fragmentation Factor subunits alpha (DFFA) and beta (DFFB), and Tumor Necrosis Factor Receptor
Superfamily Members 9 and 25 (TNFRSF9, TNFRSF25). We compared expression levels of these 5
genes in pairs of 1p-loss and 1p-intact tumors using quantitative reverse-transcriptase PCR
(QRTPCR) to test if 1p deletions had an effect on expression. Only the DFFB gene demonstrated
decreased expression in all tumor pairs tested. Mutational analysis did not reveal DFFB mutations
in 12 tested samples. However, it is possible that DFFB haploinsufficiency from 1p allelic loss is a
contributing factor in oligodendroglioma development.
Introduction
Oligodendroglial tumors with allelic losses on 1p usually
display loss of relatively long regions, a phenomenon that
has made the identification of putative 1p tumor suppres-
sor genes difficult [1-6]. However, the vast majority of
reported oligodendroglioma cases with 1p-loss have
involved the 1p36 region, with several breakpoints within
the region observed [5-9]. It is important to note that sev-
eral apoptotic genes have been mapped to 1p36. Dimin-
ished apoptosis has been recognized as one of the
hallmarks of most types of cancer, representing one of the
major ways known for a tumor-cell population to expand
[10]. Therefore, we tested TP73, TNFRSF9, TNFRSF25,
DFFA, and DFFB, all of which are 1p genes involved in
apoptosis, for differential expression in 1p-status subsets
of oligodendroglioma. QRTPCR analysis of match-paired
samples demonstrated that levels of DFFB were decreased
in all 1p-allelic loss cases. In contrast, the other tested
genes showed heterogeneous patterns of expression. This
result suggests DFFB to be a key molecule affected by 1p-
deletion in oligodendroglioma.
Materials and methods
Samples
The records of 177 patients who underwent treatment for
oligodendroglial tumors at the University of Texas M.D.
Anderson Cancer Center (UTMDACC) between 1981 and
2002 were collected and reviewed. These patients were
initially diagnosed as having low-grade oligodendrogli-
oma or mixed oligoastrocytoma, anaplastic
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oligodendroglioma or mixed oligoastrocytoma, or gliob-
lastoma multiforme with significant oligodendroglial
component by neuropathologists from UTMDACC and
later confirmed by two of the authors (KA and GF). Mixed
tumors were included in this study since clear pathologic
discrimination between glioma subtypes is sometimes
difficult, and as a group, oligoastrocytomas often have 1p
deletions [4]. In fact, both the oligodendroglial and astro-
cytic components of mixed tumors have been observed to
have this genetic signature [4].
Tissue for DNA isolation was obtained from paraffin-
embedded samples. Each tissue block was histologically
assessed for tumor by a neuropathologist (KA). Sections
were directly cut from the block for DNA isolation if at
least 90% of the tissue was determined to be tumor. If the
proportion of tumor was <90%, 10 to 20 unstained slides
were prepared from the block and tumor tissue was dis-
sected from normal tissue. DNA was isolated by digesting
deparaffinized tumor sections for 3 to 5 days with protei-
nase K at 55°C (0.5 mg/ml in 100 mmol/L NaCl, 10
mmol/L Tris-HCl, pH 8.0, 25 mmol/L ethylenediamine-
tetraacetic acid, 0.5% sodium dodecyl sulfate), followed
by a phenol:chloroform:isoamyl alcohol extraction and
isopropanol precipitation.
Tissue for RNA isolation was obtained from fresh/frozen
samples. Each frozen section was histologically assessed
for tumor by a neuropathologist (GF or KA) and used only
if at least 90% of the tissue was determined to be tumor.
For RNA isolation, up to 50 mg of tissue was frozen in liq-
uid nitrogen, crushed into powder using a mortar and pes-
tle, and dissolved in 1 ml of Trizol® Reagent. 200 µl
chloroform was added to the sample, vortexed at high
speed for 15 seconds, and centrifuged at 12,000 × g for 15
minutes at 4°C. After transfer of the aqueous phase to
fresh 1.5 ml Eppendorf tube, an equal volume of 70% eth-
anol was added and mixed by tube inversion. The sample
was then loaded onto a QIAGEN RNeasy® mini column
and centrifuged at 16,000 × g for 20 seconds (QIAGEN
Sciences, Germantown, MD). The column was washed
twice with 500 µl of QIAGEN's RPE buffer. RNA was elu-
ated off the column in 50 µl of nuclease-free water. RNA
was quantified using a spectrophotometer and qualitated
with an Agilent BioAnalyzer 2100 (Agilent Technologies,
Palo Alto, CA).
Detection of 1p allelic loss
Quantitative Microsatellite Analysis (QuMA) was used as
previously described to determine 1p allelic loss in 177
tumors in this study [11-13].
Quantitative Reverse Transcription-Polymerase Chain 
Reaction (QRTPCR) Analysis
Initial experiments were performed to determine the valid
range of RNA concentrations and to demonstrate the sim-
ilarity of PCR efficiencies for each gene of interest com-
pared to the endogenous control gene cyclophilin. To
determine fold-changes in each gene, QRTPCR was per-
formed on the ABI Prism 7700 using the commercially
available gene expression assay for p73, DFFA, and DFFB
(Hs00232088_m1, Hs00189336_m1, Hs00237077_m1,
respectively) and the cylophilin Vic-labeled Pre-Devel-
oped Assay Reagent (Applied Biosystems, Foster City, CA)
without multiplexing. In triplicate, we amplified 50 ng
cDNA for each sample for each assay in a reaction contain-
ing 1× TaqMan®  Universal PCR Master Mix without
AmpErase UNG and 1× gene expression assay with the fol-
lowing cycling conditions: 10 minutes at 95°C, then 45
cycles of 95°C for 15 seconds and 60°C for 1 minute. Cal-
culations were performed using the δδCt method to deter-
mine fold-difference in 1p-loss cases relative to the
matched 1p-intact cases. Fold changes for TNFSF5,
TNFRSF9, TNFRSF11a, and TNFRSF25 were determined
in a similar fashion, using commercially available gene
expression assays (Hs00374176_m1, Hs00155512_m1,
Hs00187189_m1, and Hs00237054_m1, respectively)
and the 18S rRNA TaqMan®  Endogenous Control
(Hs99999901_s1).
Mutation screening
PCR amplifications of exons 1–6 were carried out using
100-µL reaction volumes with 1.5 mmol/L MgCl2; 200
µmol/L each of deoxy (d)-ATP, dGTP, dTTP, and dCTP; 2
pmol of each primer; 100 ng template DNA; and 1 U
AmpliTaq Gold polymerase (Applied Biosystems, Foster
City, CA). Amplifications of exon 7 were the same with
the exception that the reaction mix had a concentration of
7% dimethylsulphoxide (DMSO). PCR cycling conditions
were 10 min at 94°C, followed by 40 cycles of 94°C for 1
min, 65°C for 1 min, and 72°C for 1 min, followed by 15
min at 72°C. Sequencing reactions were setup using the
BigDye Terminator Cycle Sequencing Reaction Kit with
AmpliTaq DNA polymerase FS (Applied Biosystems, Fos-
ter City, CA) according to the manufacturer's specifica-
tions, and were subjected to gel electrophoresis on an ABI
PRISM 3700 (Applied Biosystems, Foster City, CA).
Sequencing data were aligned with the Sequencer pro-
gram using DFFB sequence as reported by the Human
Genome Database [14]. Forward and reverse PCR primer
sequences are listed in Table 1.
Results and Discussions
We evaluated 177 oligodendroglial tumors using QuMA
for 1p-allelic loss in an attempt to determine a consensus
region of deletion [11-13]. Loss was observed in 92
tumors, which in most cases involved the entireMolecular Cancer 2005, 4:35 http://www.molecular-cancer.com/content/4/1/35
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chromosomal arm. However, six tumors demonstrated
localized loss involving the 1p36 region, defining a con-
sensus region of deletion (Figure 1). These results were
similar to those observed for other oligodendroglial 1p-
deletion mapping studies, in which consensus regions of
deletion involved 1p36 [5,6,8,9].
The second part of our strategy included the identification
of abrogated cellular pathways in oligodendrogliomas
with 1p/19q allelic loss. The transcriptsomes of eight pairs
of gender- and age-matched tumors were measured using
a Pathway microarray consisting of 1,500 functionally
characterized genes constructed in our Cancer Genomics
Core Laboratory. We used paired sample tests (the Sign
Rank test and the paired t-test) to identify differentially
expressed genes. While the sign rank test uses the null
hypothesis that the medians for the two classes are same,
the paired t-test uses the null hypothesis that the means of
the two classes are same. We recognize a gene as signifi-
cant when the sample data for the gene gives a p-value less
than 0.01 (99% confidence). This analysis revealed a
number of genes that demonstrated robust differential
expression (McDonald and Zhang, unpublished results).
We evaluated three of these genes with QRTPCR either
because of location in our consensus region of deletion
(p73), or due to their relationship to genes in our region
of interest (Tumor Necrosis Factor Super Family Ligand 5
[TNFSF5] and Tumor Necrosis Factor Receptor Super Family
11a  [TNFRSF11a]). Both TNFSF5  and  TNFRSF11a  are
involved in apoptotic pathways that include several genes
located in our region of interest: TNFRSF9, TNFRSF25,
DFFA, and DFFB. Therefore, these genes were also tested
via QRTPCR to determine if they had differential gene
expression. Based on fresh/frozen tissue availability of the
original 170 cases, total RNA samples from thirteen age-
and gender-matched pairs of 1p/19q loss and intact
tumors were evaluated for differential gene expression of
p73 and the six TNF pathway genes. Of the seven genes,
only DFFB was differentially expressed in all 13 pairs of
Table 1: Primer sets used for amplifying and sequencing the coding regions of DFFB.
Name F primer seq R primer seq
DFFBamp1 gcttgcagagctcaccaggtgc cggctgaggcgaacgaaaactacc
DFFBseq1 acggatctgagcagctgg ctcctattctccccacacgc
DFFBamp2 aagcacagctcattccggtcg tgatgggcacctggagctaagc
DFFBseq2 gccctcgtcttgagacc aggacctcggagagtgc
DFFBamp3 gggggaagatgtggtcagaggctc ccacctgagtccttgctgggtacc
DFFBseq3 cttgtgaccggggcag atccaacttcttctggcacc
DFFBamp4 gctgtagtaagctgtgttcgtgccactg gcgctagcttccctcaccagagc
DFFBseq4 ggaggacagagcaagacc ccagatccacgcaagc
DFFBamp5 gggtctcagagggccatggag cctgtgtgcactgcagcttgagag
DFFBseq5 atggatcgagagccagtg ggcaagggctgaaggtc
DFFBamp6 cgggaggcggaggttgtagtaagc ctgggctgtaacacgggtgcag
DFFBseq6 gccactgcactccagc ccatggcagggacagg
DFFBamp7 gggaatttgtgaagagctgtgactgc ccccaacaattcagaaatgtaatgaaatcag
DFFBseq7 gctatgacctgttgcctgtg ggcacctgttaaaatgatgc
Common region of allelic loss on the short arm of chromo- some 1 in oligodendrogliomas Figure 1
Common region of allelic loss on the short arm of chromo-
some 1 in oligodendrogliomas. Markers used for screening 
1p-allelic loss and their placement on the genetic and cytoge-
netic maps of 1p. Black squares indicate where tumors 
retained allelic balance, whereas gray squares indicate allelic 
loss.
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tumor samples (Figure 2). Figure 2 also displays the differ-
ential expression levels for DFFA and TP73 for the tested
tumor pairs. In contrast to DFFB, there were 3 pairs (25%)
in which the 1p/19q loss tumors had higher DFFA expres-
sion. Likewise, 5 of the 13 pairs (38%) had higher TP73
expression in the 1p/19q loss tumors. Similarly, 33%,
50%, 50%, and 83% of tested pairs had higher expression
of TNFSF5, TNFRSF9, TNFRSF11a, and TNFRSF25 in the
1p/19q loss tumors, respectively (data not shown). Since
DFFB  was the only tested gene that was differentially
expressed in the same direction by all 13 pairs of tumors,
we viewed DFFB as the best tumor suppressor gene candi-
date in our study.
We addressed the candidacy of DFFB as an oligodendrog-
lioma tumor suppressor gene by mutation analysis.
Twelve tumors with 1p-allelic loss were screened for
mutations by sequencing the 1.2 kb coding region of
DFFB. No coding region mutations were detected in any
of the samples, which may indicate that haploinsuffi-
ciency of DFFB is enough of a genetic insult to contribute
to tumorigenesis. In order to thoroughly test this hypoth-
esis, it will be necessary to further investigate DFFB, per-
haps by determining if the DFFB  promoter has been
hypermethylaed and/or if intronic sequence has been
mutated in tumor samples.
DFFB-null mouse lines have been established via gene tar-
geting [15]. Resultant mice developed normally but their
lymphocytes were more susceptible to DNA damage.
These animal model experiments suggest that DFFB is a
weak tumor suppressor, which may only manifest its
function in the presence of stress and DNA damage. Brain
tissue samples from three six-month-old specimens
revealed neuropil spongiosis, but no tumor development
was observed (data not shown). We are not clear at
present the implication of the neuropil spongiosis pheno-
type. Consistent with our data, a sequencing effort in a
neuroblastoma study did not reveal a tumor-specific
mutation in DFFB [16]. The gene expression level of DFFB
was not analyzed in that study.
Thus, this study revealed that attenuated expression of the
DFFB gene is a signature of oligodendrogliomas with 1p-
allelic loss. Since DFFB contributes to both chromosomal
condensation and DNA degradation during apoptosis,
decreased expression of DFFB may subject cells to DNA
damage stresses, which in turn may contribute to both
tumorigenesis and better response to DNA damaging
chemotherapy. Further studies are needed to investigate
the role of the DFFB  gene in the etiology of
oligodendroglioma.
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QRTPCR results in oligodendroglioma subsets Figure 2
QRTPCR results in oligodendroglioma subsets. Black bar, 1p-
intact samples; light gray bars, 1p-loss samples. A) Expression 
of DFFB was lower in all 1p-loss samples as compared to 
their matched 1p-intact samples. Ten of the thirteen 1p-loss 
tumors had lower expression of DFFB compared to normal 
brain, with three tumors demonstrating 1–2× the amount of 
normal brain DFFB expression. In contrast, all 1p-intact 
tumors had DFFB expression greater than or equal to that 
seen in normal brain. B) Expression of DFFA was lower in 
most 1p-loss samples as compared to their matched 1p-
intact samples. Only three 1p-loss tumors had higher DFFA 
expression. Differential expression was detected to a degree; 
most 1p-loss tumors (10 of 12) demonstrated 1–2× the 
amount of normal brain DFFA expression, whereas most 1p-
intact tumors (9of 12) demonstrated ≥ 2× the amount of 
normal brain DFFA expression. C). Differential p73 expres-
sion was not detected. In five of the pairs, 1p-loss tumors had 
higher expression, whereas in seven other pairs, 1p-intact 
tumors had higher expression.
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